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ABSTRACT
Serologic responses to T cell–dependent vaccinations are severely attenuated in patients with ESRD, but
the reasons for this is unknown. In this study, a detailed analysis of antigen-specific T cell responses was
performed. Patients on hemodialysis and age- and gender-matched healthy control subjects were
vaccinated with hepatitis B surface antigen (HBsAg), antigen-specific CD4 T cells were monitored at
regular intervals with intracellular cytokine staining and proliferation assays. IL-2– and IFN-–producing
CD4 T cells were identified as either central or effector memory CD4 T cells using antibodies directed
against CD45RO and the chemokine receptor CCR7. Control subjects mounted a memory T cell
response comprising both central and effector memory CD4 T cells, with the central memory response
occurring 1 wk before the effector memory response. IL-2 HBsAg-specific memory CD4 T cells were
primarily detected within the effector population. Patients with ESRD showed a delayed response of
IL-2– and IFN-–producing central memory CD4 T cells, but their maximal responses were similar to
those of control subjects. In contrast, patients with ESRD produced only 6.3% of the IL-2 HBsAg-
specific effector memory CD4 T cells produced by control subjects (0.5  0.2  104/L versus 8  3.5 
104/L; P  0.001), and this impaired response correlated with antigen-specific T cell proliferation and
anti-HBsAg IgG titers. In conclusion, the production of antigen-specific effector memory CD4 T cells
after vaccination, which is critical to achieve an adequate humoral response, is severely impaired in
patients with ESRD.
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Patients with ESRD show clinical signs of an im-
mune defect characterized by an increased suscep-
tibility for infections and a decreased immune re-
sponse to T cell–dependent antigens (e.g., hepatitis
B vaccination). The precise mechanisms responsi-
ble for this immune defect are unknown; however,
changes in T cell subsets and/or function may con-
tribute substantially to the impaired cellular im-
mune response, because ESRD is associated with
lymphopenia occurring in the B and T lymphocyte
compartment.1–3 The available data on B cell func-
tion of patients with ESRD do not indicate an im-
paired function.4 The functional data on peripheral
T cells in patients with ESRD are conflicting and
obtained by using the unfractionated bulk of circu-
lating T cells.1,3,5,6
Developments in T cell research and availability
of various chemokine receptors, such as CCR7,
have enabled a dissection of the T lymphocytes in
different subsets.7,8 Themajor T cell compartments
that can be distinguished are the naive T cells
(Tnaive; antigen inexperienced) and the antigen ex-
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perienced memory T cells. The memory compartment is fur-
ther subdivided in the central memory T cells (Tcm), that home
preferentially to lymphoid organs, and the effector memory T
cells (Tem) that are able to react swiftly upon antigenic stimu-
lation.7 After de novo antigen-specific stimulation, a linear de-
velopment in T cell differentiation has been proposed, starting
with antigen-specific Tnaive that develop into Tcm and finally
Tem.7,9,10 Recently, we analyzed the composition of the circu-
lating T cells in relation to renal function and showed a strong
depletion of the Tnaive and CD4 Tcm compartment.11,12
To gain further insight into the function of T cells in pa-
tients with uremia, it is necessary to identify the specific anti-
genic response on the single-cell level in the different T cell
subsets. In addition, this response needs to be monitored in
time, because kinetics may be different in healthy control sub-
jects compared with patients with ESRD. Hepatitis B surface
antigen (HBsAg) is a suitable antigen to use for such an analy-
sis. The antibody response is T helper cell type 1 dependent,13
and intracellular IL-2 and IFN- production in the antigen-
specific T cells can be reliably measured. In addition, patients
with ESRD have a well-documented decreased responsiveness
to the standard vaccination procedure.14,15 We postulated that
a difference in the development of antigen-specific CD4 T
cells might underlie the impaired serologic response to HBsAg
vaccination; therefore, in this study, we closely monitored the
antigen-specific T cell response after vaccination for HBsAg
and correlated our findings to the antibody titer obtained.
RESULTS
Kinetics of HBsAg-Specific Cytokine-Producing T
Lymphocytes
In healthy control subjects, the maximal response (peak re-
sponse) for IL-2 T cells was observed in the Tnaive and Tcm
subsets as early as 1 wk after the HBsAg booster and followed
by a peak response at 2 wk in the Tem subset; however, delayed
kinetics were observed for patients with ESRD, with the aver-
age peak responses in Tnaive, Tcm, and Tem subsets at 2 wk
(Figure 1, A, C, E, and G). For IFN- antigen-specific T cells,
the development in time differed from IL-2 cells. In healthy
control subjects, the peak response of IFN-HBsAg-specific
T cells was at 2wk in all T cell subsets. In addition, IFN-Tcm
and Tnaive cells were not detectable in the circulation at 4 wk
but reappeared at 12 wk. A similar profile was observed for
patients with ESRD, with the exception of a delayed peak re-
sponse at 4wk in the Tcm subset (Figure 1, B,D, F, andH). The
sequential development in time of IL-2 and IFN-HBsAg-
specific T cells within the defined T cell subsets was similar
when expressed in total numbers of cells (data not shown).
Peak Responses and Absolute Numbers of HBsAg-
Specific Cytokine-Producing T Lymphocytes
The peak response of HBsAg-specific T cells in every T cell
subset was taken to compare the maximally achieved antigen-
specific T cell responses after HBsAg vaccination for patients
and control subjects. We previously showed that patients with
ESRD differ from healthy control subjects in the absolute
numbers and composition of their circulating T cell subsets.11
To compare the peak responses between patients and healthy
control subjects, we took these observations into account and
Figure 1. Kinetics of HBsAg-specific IL-2– and IFN-–producing
CD4 T lymphocytes in the study population. PBMC were stim-
ulated with CD28 and CD49d and HBsAg for 6 h in the pres-
ence of Brefeldin A for the last 5 h of incubation. Thereafter, the
percentage of IL-2 (A, C, E, and G) or IFN- (B, D, F, and H)
cells was determined for the different T cell subsets. T cell subsets
were defined by expression of cell surface markers CD4,
CD45RO, and CCR7. The following subsets were defined Tnaive
(CD4CD45ROCCR7), Tcm cells (CD4CD45ROCCR7), and
Tem cells (CD4CD45ROCCR7). f, Signals observed for
healthy volunteers; , signals observed for patients with ESRD.
On the x axis, the various time intervals are depicted, and on the
y axis, mean  SEM percentages of HBsAg-specific cytokine-
producing CD4 (A and B), Tnaive (C and D), Tcm (E and F), and
Tem (G and H) cells are displayed, respectively. *Significantly (P
0.05) different from healthy volunteers.
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calculated absolute numbers of cytokine-producing cells. Of
note, the average absolute number of total CD4 T cells and
differentiation within subsets did not significantly change dur-
ing the study period in both patients and control subjects (data
not shown). The average (SEM) peak responses for patients
with ESRDwithin the naive CD4 compartment were not dif-
ferent from healthy volunteers and amounted to 2  0.9 
104/L and 6  2.8  104/L for IL-2 (Figure 2A) and IFN-
(Figure 2B), respectively. Also, no significant difference was
observed when peak responses within the Tcm compartment
were plotted. Numbers were 1  0.2  104/L (patients with
ESRD) versus 2  0.6  104/L (healthy volunteers) and 4 
1.6  104/L versus 2  0.5  104/L for IL-2 (Figure 2C) and
IFN- (Figure 2D), respectively. Strikingly, decreased num-
bers were noticed for HBsAg-specific IL-2–producing (Figure
2E) Tem lymphocytes. Average numbers for HBsAg-specific
IL-2–producing Tem cells amounted to 0.5 0.2 104/L and
8 3.5 104/L (P 0.01) for patients with ESRD and healthy
volunteers, respectively.
Polyclonal T Cell Stimulation
Peripheral bloodmononuclear cells (PBMC) obtained at every
point in time after vaccinationwere stimulated polyclonal with
phytohemagglutinin (PHA). No significant changes in time
were observed with respect to percentages of cytokine-positive
cells. Significantly increased percentages of IL-2–producing
cells were observed for patients with ESRD compared with
healthy control subjects within the total CD4, in particular
the memory compartment (Figure 3A). Percentages of PHA-
induced IFN-–producing cells were significantly higher in the
total CD4 compartment of patients with ESRD (Figure 3B).
Cytokine Production after Re-stimulation of HBsAg-
Specific T Cells
Type 2 cytokines, such as IL-4 and IL-10, were detected in both
healthy volunteers and patients with ESRD at low levels com-
pared with IFN-, confirming our observations with intracel-
lular cytokine staining. IL-2 was detected at low levels, which is
most likely caused by autocrine consumption by proliferating
T cells. No significant differences were observed between pa-
tients and healthy controls (Figure 4).
Figure 2. Peak responses for HBsAg-specific IL-2– and IFN-–
producing cells. Peak responses of absolute numbers of HBsAg-
specific IL-2– and IFN-–producing naive (A and B), central mem-
ory (C and D), and effector memory (E and F) CD4 T lymphocytes
obtained within 4 wk after HBsAg vaccination. Absolute peak
numbers of cells producing HBsAg-specific IL-2 and IFN- are
displayed for healthy control subjects (f) and patients with ESRD
().
Figure 3. (A and B) PHA-induced IL-2–producing (A) and IFN-–
producing (B) CD4 T lymphocytes in study population. Similar as
described in Figure 1, percentages of IL-2–producing (A) and
IFN-–producing CD4 T cells induced by PHA were determined.
On the y axis, the percentages of cytokine producing cells
(mean SEM) are displayed and on the x axis, the different CD4
T cell subsets. f, signals observed for healthy volunteers; ,
signals for patients with ESRD. *Significantly (P  0.05) different
from healthy volunteers.
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HBsAg-Specific T Cell Proliferation
HBsAg-specific proliferation was significantly decreased when
compared with healthy volunteers, but the maximal responses
were observed at the same time point (i.e., 2 wk upon receipt of
the last HBsAg vaccination; Figure 5). PHA-induced prolifer-
ation, expressed as stimulation indices, was not different
(77.8 12.8 for patients with ESRD versus 54 8 for healthy
individuals). HBsAg-specific proliferation was related only to
responses observed for Tem CD4 T cells (the Spearman rank
correlation coefficient amounted to 0.613 [P 0.01] and 0.425
[P 0.05] for percentage of IL-2 and IFN- effectormemoryT
lymphocytes, respectively).
Antibody Titers and Relation with Development of
HBsAg-Specific T Cells
Average anti-HBsAg IgG titers amounted to 172 61 IU/L for
patients with ESRD and 33,936 16,446 IU/L for healthy vol-
unteers. Six of the 16 patients with ESRD did not acquire ade-
quate antibody titers, and five patients achieved titers between
10 and 100 IU/L (Figure 6). These titers were related exclu-
sively to the peak responses of IL-2HBsAg-specific Tem, ex-
pressed both as percentages (Figure 7A) of the total number of
Tem and in absolute numbers (Figure 7B). Such a relation was
observed within the group of patients and healthy control sub-
jects separately and when combined. Anti-HBsAg IgG titers
also correlated with the maximum antigen-specific prolifera-
tive response (R  0.455, P  0.015) obtained after vaccina-
tion.
DISCUSSION
In this study, we analyzed the development and characteristics
of vaccination-induced HBsAg-specific CD4 T cells in pa-
Figure 4. Levels of HBsAg-specific cytokines produced after re-
stimulation. PBMC, obtained 2 wk after receipt of the last HBV
booster vaccination, were stimulated with HBsAg (5 g/ml;
squares) or polyclonal with PHA (1 g/ml; triangles). At day 6, the
cells were re-stimulated for 48 h using fresh PBMC (1  105) with
or without the various stimuli. The closed symbols represent
healthy control subjects, and the open symbols represent the
patients with ESRD.
Figure 5. Kinetics of HBsAg-specific proliferation. At the various
intervals, freshly isolated PBMC were stimulated with medium
alone and HBsAg (5 g/ml) for 6 d. At day 6, proliferation was
determined by 3H-thymidine incorporation and is expressed as
counts per minute (cpm). Subsequently, stimulation indices (SI)
were calculated by dividing the HBsAg-induced proliferation by
that induced by culture medium alone. On the x axis, various time
intervals after the last HBV vaccination are depicted and on the y
axis, proliferation expressed as SI. f, Responses for healthy vol-
unteers; , responses for patients with ESRD. *Significantly (P 
0.05) different from healthy volunteers.
Figure 6. Anti-HBsAg titers. Four weeks after receipt of the last
HBV vaccination, anti-HBsAg titers were measured. On the y axis,
anti-HBs titers (IU/L) are depicted, and on the x axis, the healthy
volunteers (f) and patients with ESRD (). The dotted lines
represent the 10 IU/L (nonresponders) and 100 IU/L (good
responders).
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tients with ESRD. The major observations include a delayed
development of antigen-specific cells in the Tcm subset, defec-
tive or almost absent generation of antigen-specific IL-2 Tem,
and decreased HBsAg-specific T cell proliferation.
The generation of IL-2HBsAg-specific T cells supports the
hypothesis of a linear development in time of antigen-experi-
enced T cells, with the peak of Tcm preceding the peak in Tem
response. Patients with ESRD showed a similar sequence in
time as healthy control subjects, but a delayed development of
antigen-specific cells in the central memory compartment was
observed. Development of antigen-specific memory T cells af-
ter vaccination involves many steps of which the underlying
mechanisms are only partly unraveled. Antigen within the pe-
ripheral tissue needs to be delivered to the draining lymph
node by dendritic cells and presented to antigen-specific T
cells. These cells must reach the T cell–dependent areas within
the lymph node by chemokine receptor–mediated trafficking,
proliferate, and thereafter start recirculating again. All steps in
this process may be affected in patients with ESRD but are
poorly studied in humans thus far. Because the number of
peripheral dendritic cells is decreased in patients with
ESRD,16–18 one may speculate that the number of antigen-
loaded dendritic cells migrating to the draining lymph nodes is
decreased. Also, chemokine receptor expression on circulating
T cells is changed in patients with ESRD,whichmay have func-
tional consequences11; however, functional data on chemokine
receptor–mediated migration are not available.
The most striking finding was the poor development of
IL-2 Tem in patients with ESRD, which was strongly associ-
ated with a low serologic response to HBsAg. Although the
development of IFN-HBsAg-specific T cells in patients was
different from that in healthy control subjects, no association
was found between IFN- T cell development and serologic
response. The unique relation between IL-2 Tem and anti-
body titer was observed in healthy control subjects and pa-
tients, with patients with ESRD at the lower end of a seemingly
continuous curve. This indicates that the generation of IL-2
Tem is directly related to and possibly pivotal for the develop-
ment of IgG-secreting plasma cells from antigen-specific B
cells. A functional role of IL-2 secreted by antigen-specific T
cells seems plausible, because IL-2 has been identified as an
important cytokine in the final differentiation pathway of B
cells into antibody secreting cells. The majority of memory B
cells express the IL-2 receptor,19 and late in a primary immune
response, the IL-2 secreted by antigen-activated T helper cells
binds to high-affinity IL-2 receptors on antigen-activated B
cells.20 IL-2 then acts on two crucial regulators of B cell devel-
opment, the Pax5 gene–encoded transcription factor B cell
lineage–specific activator protein and Blimp-1.21,22 Blimp-1 is
a member of the zinc finger–containing family of DNA-bind-
ing proteins and is the master switch for the terminal differen-
tiation of B cells into plasma cells.23 In accordance with these
findings, the presence of T cells can be replaced by exogenous
IL-2 in an in vitromodel of antigen-specific T cell–dependent
differentiation of B cells to plasma cells.24
Remarkably, recent data suggest that after vaccination for
other antigens such as HIV (peptide pool to envelope clade A)
and tetanus toxoid, the dominant response also consisted of
IL-2 memory T cells13; therefore, development of an IL-2 T
cell memory response seems necessary for an adequate hu-
moral response to vaccination.More specific, our data indicate
that the generation of IL-2–producing Tem is a condition sine
qua non for a serologic response after vaccination. This finding
sheds new light on the observation in the past that administra-
tion of IL-2 is able to enhance the response to hepatitis B virus
(HBV) vaccination in patients with ESRD.25
At this point, we can only speculate why the development of
HBsAg-specific IL-2 Tem is so disturbed in patients with
ESRD. In general, generation of memory T cells involves cyto-
kines (e.g., IL-7, IL-15) and efficient stimulation by antigen-
Figure 7. (A and B) Peak responses for both percentages (A) and
absolute numbers (B) of HBsAg-specific IL-2 effector memory
CD4 T cells correlate with anti-HBsAg titers. Peak responses for
HBsAg-specific percentages and absolute numbers of IL-2–pro-
ducing effector memory CD4 T cells are associated with anti-
HBsAg titers measured 4 wk after the last HBV vaccination. On the
x axis, anti-HBs titers (IU/L) are depicted, and on the y axis,
percentages (A) and absolute numbers (B) of HBsAg-specific IL-
2–producing effector memory CD4 T cells are displayed. f,
Responses for healthy volunteers; , responses for patients with
ESRD. Spearman rank correlation was calculated using SPSS for
Windows.
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presenting cells. As stated before, the latter function may be
negatively affected, and we observed lower serum concentra-
tions of IL-7 in patients with ESRD.11 Of particular relevance
to our data is a study that points to an important role for the
co-stimulatory pathway B7-CD28. Blocking of this pathway
withCTLA4-Ig in amousemodel of T cell stimulation by recall
antigen resulted in absent generation of antigen-specific Tem
but without affecting the Tcm response.26 In accordance with
our findings, the IL-2 and not the IFN- response was almost
exclusively affected. We recently described impaired matura-
tion of monocyte-derived dendritic cells of patients with
ESRD,27 which resulted in decreased expression of the B7mol-
ecules (CD80 and CD86). Taken together, these findings sug-
gest that dysfunctional dendritic cells in patients with ESRD
may contribute to the selective absence of IL-2 antigen-specific
Tem after vaccination. B lymphocytes might also be consid-
ered as a source of antigen-presenting cells, but whereas its
intrinsic function does not seem to be impaired,28 the numbers
of B lymphocytes present in the circulation are significantly
decreased in patients with ESRD.11
The finding of normal and even increased cytokine produc-
tion by T cell subsets after polyclonal stimulation is important.
It shows that T cells frompatients with ESRDare able to secrete
cytokines to a similar extent as in healthy control subjects.
Finally, HBsAg -specific T cell proliferation was decreased
in patients with ESRD, which can in part be explained by the
low numbers of circulating IL-2 Tem. This also explains the
relation found between anti-HBsAg titer andHBsAg-specific T
cell proliferation. Consistent with our previous findings,29 we
observed normal polyclonal T cell proliferation in patients
with ESRD, indicating no intrinsic defect in proliferative ca-
pacity.
In summary, this is the first article ascribing the aberrant
humoral immune response toHBsAg in patients with ESRD to
the defective development of antigen-specific IL-2–producing
Tem. It is difficult to apply these findings to other antigens
because we have studied only HBV vaccination; however, the
same problems might also underlie the defective antibody re-
sponse to other vaccination antigens, such as diphtheria and
tetanus.30 Understanding the factors that are important for the
development of IL-2–producing Tem may lead to improve-
ment of current vaccination protocols.
CONCISE METHODS
Study Population
Sixteen patients who had ESRD and were receiving long-term inter-
mittent hemodialysis and 17 age- and gender-matched healthy con-
trol subjects were included in the study (Table 1). Patients were vac-
cinated against HBV using the standard vaccination protocol with
recombinant hepatitis B vaccine (HBVAXPRO; Sanofi Pasteur MSD
NV, Amsterdam, Netherlands).31,32 Patients who used immunosup-
pressive agents, had autoimmune disease, had undergone kidney
transplantation, or were positive for HIV and/or hepatitis C virus
were excluded from the study. Healthy volunteers were vaccinated
using a three-step (0, 1, and 6 mo) vaccination with only half of the
dosage used for patients with ESRD per injection.
Study Protocol
This study was approved by the Medical Ethical Committee of the
Erasmus Medical Center (Rotterdam, Netherlands; Medical Ethical
Committee no. 2005-265). It was conducted according to the princi-
ples of the Declaration of Helsinki and in compliance with Interna-
tional Conference on Harmonization/Good Clinical Practice regula-
tions. Patients were followed up to 12 wk upon receipt of their last
HBV vaccination step. At each interval (before and 1, 2, 4, and 12 wk
after receiving the last booster), blood was drawn at the start of the
hemodialysis procedure. PBMCwere isolated, and plasma was stored
at20°C until analysis.
Isolation of PBMC
PBMC were isolated from 35 ml of heparinized venous blood sam-
ples27 and resuspended in RPMI 1640 (Gibco BRL, Paisley, Scotland)
supplemented with 100 IU/ml penicillin, 100 g/ml streptomycin, 2
mM L-glutamine, and 10% heat-inactivated AB pooled human se-
rum (hereafter referred to as standard culture medium).
Intracellular Cytokine Staining
Intracellular cytokine staining was performed using co-stimulation
alone (mixture of 1g/ml anti-CD28 and 1g/ml anti-CD49d) or in
combination with a final concentration of 5g/mlHBsAg (Fitzgerald
Industries Int., Concord, MA) or 1 g/ml PHA (Murex Biotech Ltd.,
Kent, England) to stimulate PBMC.13,33 After permeabilization, cells
were stained with either FITC-labeled IL-2 or FITC-labeled IFN-,
and percentages of cytokine-positive cells were determined by analyz-
ing the samples on the FACS Calibur (BD, Erebodegem, Belgium),
selecting cells that have a typical lymphocyte scatter pattern and are
CD4 (Figure 8, A and B). Antigen-specific T cells were characterized
by staining the cell surface with peridinin chlorophyll protein–labeled
anti-CD4, allophycocyanin-labeled CD45RO (both from Becton
Dickinson, Erebodegem, Belgium), and phycoerythrin-labeled CCR7
(R&D Systems Europe Ltd., Abingdon, UK) to dissect the different
CD4 T cell subsets.11 The different CD4 T cell subsets
(CCR7CD45RO [Tnaive], CCR7CD45RO [Tcm], and
CCR7CD45RO [Tem]) were analyzed as shown in Figure 8C and
described previously.11 A typical example of percentages of IL-2–pro-
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ducing CD4 Tem cells is shown in Figure 8, D through I. HBsAg-
specific responses could not be detected in the CD4 T cell subsets of
patients and control subjects who were not vaccinated with HBsAg
(data not shown).
Proliferation (3H-Thymidine Incorporation)
To determine antigen-specific proliferation, we used the protocol de-
scribed by Verkade et al.27 Results are presented as stimulation indi-
ces, calculated by dividing the proliferation (in counts per minute)
induced by the stimulus by that observed in absence of the stimulus
(in counts per minute).
Antigen-Specific Cytokine Production
Two weeks after receiving the last vaccination for HBV, 1  105
PBMC/100 l in a round bottom–shaped 96-well plate were stimu-
lated for 6 d in the presence of recombinant HBsAg (5 g/ml), PHA
(1 g/ml), or standard culture medium
alone. On day 6, the supernatant was dis-
carded and cells were re-stimulated by add-
ing fresh autologous PBMC (1  105), with
or without the same stimuli as used in the
primary culture. Supernatants were col-
lected 48 h after re-stimulation, and the
levels of IL-2, -4, -6, and -10; IFN-; and
TNF- were determined by flowcytometry
(cytometric bead array; BD).
Anti-HBsAg Titer
Anti-HBsAg IgG titers were determined 4 wk
after receipt of last vaccination in plasma
using the Enzyme Immuno Assay (AxSym;
Abbott Diagnostics, Hoofddorp, Nether-
lands) according to the manufacturer’s
instructions.
Statistical Analysis
Statistical analyses were performed using
SPSS 11.5 for Windows (SPSS, Chicago, IL).
Data are mean SEM unless indicated oth-
erwise. Comparison between patients with
ESRD and healthy control subjects was done
using the nonparametric Mann-Whitney U
test. For testing whether relations between
the different parameters exist, the nonpara-
metric Spearman rank correlation was deter-
mined. P 0.05 were considered statistically
significant.
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